The tailored activity program for people living with dementia: a two-arm randomised waitlist-controlled trial with 24-week follow-up

To evaluate the effects of the evidence-based Tailored Activity Program (TAP) on neuropsychiatric symptoms (NPS) and cognitive function among people living with dementia (PLWD), as well as the well-being of their caregivers in China. A single-blind, two-arm randomised waitlist-controlled trial was conducted. A total of 64 PLWD-caregiver dyads were enrolled from January 2022 to December 2023 and randomly assigned to either the TAP intervention group (n = 32) or waitlist control group (n = 32). The TAP intervention group received two consecutive 12-week TAP cycles (Cycle 1: weeks 1–12; Cycle 2: weeks 13–24). Each cycle adopted the three-stage assessment-implementation-generalisation framework, consisting of eight visits (five home visits and three telephone follow-ups). All visits were delivered within each 12-week intervention period rather than serving merely as maintenance follow-ups. The control group received standard community home-visiting services in the first 12 weeks, followed by the identical TAP intervention in the subsequent 12 weeks. Data were collected at baseline (T0), week 12 (T1), and week 24 (T2). Primary outcomes included neuropsychiatric symptoms, cognitive function, and quality of life of PLWD. Secondary outcomes comprised caregiver burden and depressive symptoms. In this waitlist-controlled trial, linear mixed-effects models revealed significant time-by-group interactions for NPI, QOL-AD, ZBI and CES-D. At T1 and T2, large-magnitude between-group differences favoured the intervention: NPI (T1: -15.22, 95% CI -22.87 to -7.56, Cohen’s d = 1.059; T2: -16.46, 95% CI -24.11 to -8.80, Cohen’s d = 1.250); QOL-AD (T1: 3.86, 95% CI 2.02 to 5.70, Cohen’s d = 1.131; T2: 3.25, 95% CI 1.41 to 5.09, Cohen’s d = 0.901); ZBI (T1: -10.61, 95% CI -15.92 to -5.30, Cohen’s d = 0.906; T2: -11.49, 95% CI -16.80 to -6.18, Cohen’s d = 1.041); CES-D (T1: -6.37, 95% CI -9.82 to -2.92, Cohen’s d = 0.932; T2: -6.06, 95% CI -9.50 to -2.61, Cohen’s d = 1.090). These findings suggest potential clinical benefits in reducing neuropsychiatric symptoms, improving quality of life for PLWD, and lowering caregiver burden and depressive symptoms. For MMSE, no significant time, group or interaction effects were detected; borderline between-group differences (T1: 2.80, 95% CI -0.11 to 5.71; T2: 2.84, 95% CI -0.07 to 5.75) with small-to-moderate effect sizes provided insufficient evidence of cognitive improvement. TAP was associated with large improvements in neuropsychiatric symptoms and quality of life for PLWD, as well as reductions in caregiver burden and depressive symptoms. No consistent evidence of cognitive benefits was identified. Owing to limitations of the waitlist crossover design, 24-week follow-up findings are exploratory. Larger studies are required to examine cognitive outcomes and different intervention durations of TAP. ChiCTR2500114438. Registered on 11 December 2025 at the Chinese Clinical Trial Registry (ChiCTR, http://www.chictr.org.cn).

Authors

Institutions

Publication Details

Journal
BMC Nursing
Published
2026-11-16
DOI
https://doi.org/10.1186/s12912-026-05671-z
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The tailored activity program for people living with dementia: a two-arm randomised waitlist-controlled trial with 24-week follow-up

Laura N. Gitlin, Qirong Chen, Minhui Liu, Weimin Lou et al.
BMC Nursing
Dementia and Cognitive Impairment Research
article

The tailored activity program for people living with dementia: a two-arm randomised waitlist-controlled trial with 24-week follow-up

Laura N. Gitlin, Qirong Chen, Minhui Liu, Weimin Lou, Shijia He, Caixia Liu, Biyan Jiang, Baiyu Li, Feifei Li
article en

Abstract

To evaluate the effects of the evidence-based Tailored Activity Program (TAP) on neuropsychiatric symptoms (NPS) and cognitive function among people living with dementia (PLWD), as well as the well-being of their caregivers in China. A single-blind, two-arm randomised waitlist-controlled trial was conducted. A total of 64 PLWD-caregiver dyads were enrolled from January 2022 to December 2023 and randomly assigned to either the TAP intervention group (n = 32) or waitlist control group (n = 32). The TAP intervention group received two consecutive 12-week TAP cycles (Cycle 1: weeks 1–12; Cycle 2: weeks 13–24). Each cycle adopted the three-stage assessment-implementation-generalisation framework, consisting of eight visits (five home visits and three telephone follow-ups). All visits were delivered within each 12-week intervention period rather than serving merely as maintenance follow-ups. The control group received standard community home-visiting services in the first 12 weeks, followed by the identical TAP intervention in the subsequent 12 weeks. Data were collected at baseline (T0), week 12 (T1), and week 24 (T2). Primary outcomes included neuropsychiatric symptoms, cognitive function, and quality of life of PLWD. Secondary outcomes comprised caregiver burden and depressive symptoms. In this waitlist-controlled trial, linear mixed-effects models revealed significant time-by-group interactions for NPI, QOL-AD, ZBI and CES-D. At T1 and T2, large-magnitude between-group differences favoured the intervention: NPI (T1: -15.22, 95% CI -22.87 to -7.56, Cohen’s d = 1.059; T2: -16.46, 95% CI -24.11 to -8.80, Cohen’s d = 1.250); QOL-AD (T1: 3.86, 95% CI 2.02 to 5.70, Cohen’s d = 1.131; T2: 3.25, 95% CI 1.41 to 5.09, Cohen’s d = 0.901); ZBI (T1: -10.61, 95% CI -15.92 to -5.30, Cohen’s d = 0.906; T2: -11.49, 95% CI -16.80 to -6.18, Cohen’s d = 1.041); CES-D (T1: -6.37, 95% CI -9.82 to -2.92, Cohen’s d = 0.932; T2: -6.06, 95% CI -9.50 to -2.61, Cohen’s d = 1.090). These findings suggest potential clinical benefits in reducing neuropsychiatric symptoms, improving quality of life for PLWD, and lowering caregiver burden and depressive symptoms. For MMSE, no significant time, group or interaction effects were detected; borderline between-group differences (T1: 2.80, 95% CI -0.11 to 5.71; T2: 2.84, 95% CI -0.07 to 5.75) with small-to-moderate effect sizes provided insufficient evidence of cognitive improvement. TAP was associated with large improvements in neuropsychiatric symptoms and quality of life for PLWD, as well as reductions in caregiver burden and depressive symptoms. No consistent evidence of cognitive benefits was identified. Owing to limitations of the waitlist crossover design, 24-week follow-up findings are exploratory. Larger studies are required to examine cognitive outcomes and different intervention durations of TAP. ChiCTR2500114438. Registered on 11 December 2025 at the Chinese Clinical Trial Registry (ChiCTR, http://www.chictr.org.cn).

BMC Nursing
Central South University (CN), Zhejiang Hospital (CN), Ningxia Medical University (CN), Drexel University (US)
National Key Research and Development Program of China
Good health and well-being
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon